Enzalutamide Receives Positive EU CHMP Opinion for High-Risk Biochemically Recurrent nmHSPC
The EMA’s CHMP has recommended the approval of enzalutamide with or without androgen deprivation therapy in biochemically recurrent nmHSPC.
The EMA’s CHMP has recommended the approval of enzalutamide with or without androgen deprivation therapy in biochemically recurrent nmHSPC.
Celebrate and Show Appreciation for Oncology Nursing Month with gifts offered by Jim Coleman, ltd. and ONS and the Oncology Nursing Foundation.
Prevention committee The Prevention Committee was established in 2019 to fulfil the ESGO vision: Best treatment and prevention in gynaecological cancer. ESGO has set as its…
The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free survival in newly diagnosed, high-risk endometrial cancer.
A patient-reported outcome (PRO) analysis from the phase III TOPAZ-1 trial showed no “detrimental effect” with the addition of durvalumab to gemcitabine/cisplatin in patients with…
Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.
MD Anderson Cancer Center and the Pan American Health Organization are collaborating to strengthen cancer prevention and control initiatives across the Americas. To access this…
A phase 3 study evaluating uproleselan in relapsed/refractory acute myeloid leukemia missed its primary end point of overall survival.
The novel EHA/EBMT grading of ICAHT closely reflects the extent of hematological toxicity following BCMA- and CD19-directed CAR-T therapy.Severe ICAHT was
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development.…
Raymond Douglas, MD, PhD, clinician and thought leader in thyroid eye disease (TED), provides an overview of TED, including diagnosis challenges and current and emerging…